Clinical Site

Berlin, New Jersey 08009

0 studies enrolling now · 7 studies all time

What they study most

Bipolar Depression, Detection of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 in Individuals Exposed to SARS-CoV-2, Major Depressive Disorder, Schizophrenia

Studies at this site

• Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression — Completed
• An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Completed
• A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment — Completed
• Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Completed
• Lumateperone for the Prevention of Relapse in Patients With Schizophrenia — Completed
• Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens — Stopped early
• Clinical Trial Evaluating ITI-007 as an Adjunctive Therapy to Lithium or Valproate for the Treatment of Bipolar Depression — Completed